![Hans-Georg Capraro](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Dr. Hans-Georg Capraro is Head-Medicinal Chemistry at Oncalis AG.
Dr. Capraro was previously employed as a Principal by Ciba-Geigy AG and a Principal by Novartis AG.
He received his doctorate degree from the Swiss Federal Institute of Technology.
Former positions of Hans-Georg Capraro
Companies | Position | End |
---|---|---|
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Corporate Officer/Principal | 2011-12-13 |
NOVARTIS AG | Corporate Officer/Principal | - |
Ciba-Geigy AG
![]() Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Corporate Officer/Principal | - |
Training of Hans-Georg Capraro
Swiss Federal Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
NOVARTIS AG | Health Technology |
Private companies | 2 |
---|---|
Oncalis AG
![]() Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Health Technology |
Ciba-Geigy AG
![]() Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Hans-Georg Capraro